ESR2 and ovarian carcinoma: In a study of eight PBDE congeners and their metabolites in ERα and ERβ CALUX assays in BG1Luc4E2 ovarian cancer cells, three (BDE-28, BDE-47, and BDE-100) showed ERα-agonistic properties, BDE-100 also showed ERβ-antagonistic properties, and two other congeners (BDE-99 and BDE-153) showed antagonistic properties for both ER receptors in the μM range [136].